Recent approvals of trastuzumab deruxtecan (T-DXd; Enhertu) in early HER2-positive breast cancer have created new questions about its optimal use in the neoadjuvant and adjuvant settings.
MedPage Today brought together three expert leaders in the field: Moderator Hope S. Rugo, MD, of the City of Hope Comprehensive Cancer Center in Duarte, California, is joined by William J. Gradishar, MD, of Northwestern University Feinberg School of Medicine in Chicago, and Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute in Boston, for a virtual roundtable discussion. In this third of four exclusive episodes, the panel discusses how results from DESTINY-Breast11 and DESTINY-Breast05 may influence treatment selection for patients with early-stage HER2-positive disease.
Click here to watch the other videos from this series.
Following is a transcript of their remarks:
Rugo: Let's go on and talk about another area I think that's been very exciting is multiple approvals for T-DXd, three approvals just over the last few months. The approval in the first-line metastatic setting of T-DXd and pertuzumab [Perjeta] and then the approval in the neoadjuvant and post-neoadjuvant setting in DESTINY-Breast11 and DESTINY-Breast05. So let's just talk about the early stage first. They approved widely, fairly widely, the drug in both settings. How would you choose to use the drug and what do you think about that, Bill?
